Distinct Prognostic Factors in Patients with Stage I Non-Small Cell Lung Cancer with Radiologic Part-Solid or Solid Lesions
Overview
Pulmonary Medicine
Authors
Affiliations
Introduction: Recent studies have indicated that the presence of ground-glass opacity (GGO) components is associated with favorable survival. The purpose of this study was to reveal the prognostic value of GGO components and differences in prognostic factors for part-solid and solid lesions in invasive stage I NSCLC.
Methods: The cases of 2010 patients with completely resected invasive pathological stage I NSCLC were reviewed according to the eighth edition of the TNM classification. Patients were categorized into the pure-GGO, part-solid, and solid groups based on consolidation-to-tumor ratio. Cox multivariate proportional hazard analyses were conducted to identify independent prognostic factors in each group.
Results: Of the 2010 patients, 146 (7.3%) were in the pure-GGO group, 732 (36.4%) were in the part-solid group, and 1132 (56.3%) were in the solid group. Cox multivariate analyses revealed that GGO absence was a strong independent risk factor for worse recurrence-free survival (p < 0.001). For the pure-GGO group, there was no recurrence in spite of the invasive stage. For the part-solid group, visceral pleural invasion could not predict recurrence-free survival in general (p = 0.514) or in each tumor size group (for tumors size ≤1 cm, p = 0.664; for tumors size >1 to 2 cm, p = 0.456; for tumors size >2 to 3 cm, p = 0.900; and for tumors size >3 to 4 cm, p = 0.397). For the solid group, adenocarcinoma subtype was not a prognostic factor for recurrence-free survival in general (p = 0.162) or in each tumor size group (for tumors size ≤ 2 cm, p = 0.092; for tumors size >2 to 3 cm, p = 0.330; and for tumors size >3 to 4 cm, p = 0.885).
Conclusions: The presence of GGO components was a strong predictor in patients with invasive pathological stage I NSCLC. Risk factors were distinct in the part-solid and solid groups. There was no prognostic value of visceral pleural invasion in the part-solid group. Adenocarcinoma subtype did not have prognostic value in the solid group.
Wu Y, Xu J, Zhang K, Huang Y, Zhang J, Chen H J Cardiothorac Surg. 2025; 20(1):146.
PMID: 40050858 PMC: 11884200. DOI: 10.1186/s13019-025-03371-4.
Xin S, Wen M, Tian Y, Dong H, Wan Z, Jiang S World J Surg Oncol. 2025; 23(1):66.
PMID: 40016762 PMC: 11866629. DOI: 10.1186/s12957-025-03701-9.
Gene mutation, clinical characteristics and pathology in resectable lung adenocarcinoma.
Zou J, Han W, Hu Y, Zeng C, Li J, Lei W World J Surg Oncol. 2025; 23(1):16.
PMID: 39844176 PMC: 11752792. DOI: 10.1186/s12957-025-03680-x.
Li Y, Yang Z, Jie H, Zhang L, Guo C, Liu C Transl Lung Cancer Res. 2025; 13(12):3526-3537.
PMID: 39830748 PMC: 11736582. DOI: 10.21037/tlcr-24-664.
Luo Q, Li H, Liu X, Zheng Y, Guo T, Fan J Transl Lung Cancer Res. 2025; 13(12):3352-3363.
PMID: 39830740 PMC: 11736616. DOI: 10.21037/tlcr-24-459.